We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Verrica Parmaceuticals Inc | NASDAQ:VRCA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.69% | 7.31 | 6.67 | 7.43 | 7.36 | 7.1417 | 7.25 | 240,979 | 21:30:00 |
A live audio webcast of the event will be available in the Investors/Events & Presentations section of the Verrica website at http://www.verrica.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
About Verrica Pharmaceuticals Inc.
Verrica is a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases. The company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum and common warts. Molluscum is a highly contagious viral skin infection affecting approximately six million people, primarily children, in the United States, and common warts are contagious skin growths affecting 22 million people. There are currently no FDA-approved treatments for molluscum or common warts. Following positive topline results from two pivotal Phase 3 trials, a New Drug Application for VP-102 for the treatment of molluscum is planned for the second half of 2019. Verrica is planning to meet with the FDA to determine next steps on the development of VP-102 for common warts following positive Phase 2 results. VP-102 is also currently in a Phase 2 trial for the treatment of external genital warts. A second product candidate, VP-103, is in pre-clinical development for plantar warts. For more information, visit www.verrica.com.
Contacts
Investors:
Chris DegnanChief Financial Officer484.453.3300 ext. 103info@verrica.com
Chiara RussoSolebury Trout617.221.9197crusso@soleburytrout.com
Media:
Joshua R. MansbachSolebury Trout646-378-2964jmansbach@troutgroup.com
1 Year Verrica Parmaceuticals Chart |
1 Month Verrica Parmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions